MRNA- Leader in the vaccine race. Ladder buy to avoid the risk

NASDAQ:MRNA   Moderna, Inc
Moderna is the first company to start the phase 3 trial in July and could have the supply ready earliest by Oct and accelerated approval earliest by December, according to Nami Sumida/BioPharma Dive and morningstar .

Other competitors are scheduled to have accelerated approval the earliest around early 2021.


The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.